NO20100437L - Fremgangsmate for modifisering av frigjoringshastigheten av en biologisk aktiv forbindelse innkapslet i et multivesikulaert liposom, multivesikulaert liposom samt anvendelse derav - Google Patents

Fremgangsmate for modifisering av frigjoringshastigheten av en biologisk aktiv forbindelse innkapslet i et multivesikulaert liposom, multivesikulaert liposom samt anvendelse derav

Info

Publication number
NO20100437L
NO20100437L NO20100437A NO20100437A NO20100437L NO 20100437 L NO20100437 L NO 20100437L NO 20100437 A NO20100437 A NO 20100437A NO 20100437 A NO20100437 A NO 20100437A NO 20100437 L NO20100437 L NO 20100437L
Authority
NO
Norway
Prior art keywords
release
multivesicular liposome
neutral lipid
active compound
rate
Prior art date
Application number
NO20100437A
Other languages
English (en)
Other versions
NO333827B1 (no
Inventor
Randall C Willis
Original Assignee
Pacira Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20100437L publication Critical patent/NO20100437L/no
Application filed by Pacira Pharmaceuticals Inc filed Critical Pacira Pharmaceuticals Inc
Publication of NO333827B1 publication Critical patent/NO333827B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Frigjøringshastigheten av innkapslet aktiv forbindelse fra en multivesikulær liposom (MVL) formulering blir modifisert ved utvelgelse av en nøytral lipid/komponent. En familie av MVL- formuleringer inneholdende forskjellige molforhold av nøytralt lipid med langsom:hurtig frigjøring har forskjellige frigjøringshastigheter avhengig av molforholdet av det nøytrale lipid med hurtig frigjøring til det nøytrale lipid med langsom frigjøring i hvert medlem. Inkubering i plasma eller et plasmalignende medium ved in vivo temperatur slik at det blir oppnådd en frigjøringshastighetskurve for hver vil tillate utvelgelse fra medlemmene av familien av en liposomformulering med en ønsket frigjøringshastighet in vivo.
NO20100437A 1997-01-31 2010-03-24 Farmasøytisk preparat og anvendelse derav for forhindring eller forbedring av post-kirurgi eller post-partum smerte. NO333827B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/792,566 US5891467A (en) 1997-01-31 1997-01-31 Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
PCT/US1998/001636 WO1998033483A1 (en) 1997-01-31 1998-01-29 Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes

Publications (2)

Publication Number Publication Date
NO20100437L true NO20100437L (no) 1999-09-27
NO333827B1 NO333827B1 (no) 2013-09-23

Family

ID=25157347

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19993635A NO329401B1 (no) 1997-01-31 1999-07-27 Fremgangsmate for modifisering av frigjoringshastigheten av en biologisk aktiv forbindelse innkapslet i et multivesikulaert liposom, multivesikulaert liposom samt anvendelse derav.
NO20100437A NO333827B1 (no) 1997-01-31 2010-03-24 Farmasøytisk preparat og anvendelse derav for forhindring eller forbedring av post-kirurgi eller post-partum smerte.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO19993635A NO329401B1 (no) 1997-01-31 1999-07-27 Fremgangsmate for modifisering av frigjoringshastigheten av en biologisk aktiv forbindelse innkapslet i et multivesikulaert liposom, multivesikulaert liposom samt anvendelse derav.

Country Status (12)

Country Link
US (2) US5891467A (no)
EP (2) EP2322143B1 (no)
JP (2) JP3940177B2 (no)
AU (1) AU731038B2 (no)
CA (3) CA2277956C (no)
DK (1) DK0971699T3 (no)
ES (1) ES2529167T3 (no)
IL (1) IL131012A0 (no)
NO (2) NO329401B1 (no)
NZ (1) NZ336843A (no)
PT (1) PT971699E (no)
WO (1) WO1998033483A1 (no)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5438075A (en) 1993-03-30 1995-08-01 Skubitz; Keith M. Oral glutamine to reduce stomatitis
JP4467789B2 (ja) 1997-09-18 2010-05-26 パシラ ファーマシューティカルズ インコーポレーテッド 持続放出性リポソーム麻酔組成物
CA2309548A1 (en) 1997-11-14 1999-05-27 Skyepharma Inc. Production of multivesicular liposomes
MXPA00006196A (es) * 1998-10-23 2003-07-21 Idea Ag Metodo para desarrollar, evaluar y utilizar asociaciones de macromoleculas y agregados complejos para obtener mejores tasas de asociacion/desasociacion controlable y carga efectiva.
JP2002533379A (ja) 1998-12-23 2002-10-08 イデア アクチェンゲゼルシャフト 生体内における局所的に非侵襲性である用途のための改善された製剤
CA2374003C (en) 1999-05-17 2008-02-12 Aesgen, Inc. Improved cellular uptake of bioactive agents
EP1189597A4 (en) * 1999-06-04 2008-06-18 Pacira Pharmaceuticals Inc COMPOSITIONS USING AN OIL CORE FOR DELAYED RELEASE HYDROPHOLE MEDICAMENTS
CN1116875C (zh) * 2000-10-19 2003-08-06 南京振中生物工程有限公司 紫杉醇脂质组合物及其制备方法
US20030180348A1 (en) * 2002-03-22 2003-09-25 Levinson R. Saul Transcellular drug delivery system
CA2489919A1 (en) * 2002-07-03 2004-01-15 Aphton Corporation Liposomal vaccine
US20050169979A1 (en) * 2002-07-03 2005-08-04 Dov Michaeli Liposomal vaccine
US20040247661A1 (en) * 2002-07-03 2004-12-09 Dov Michaeli Liposomal vaccine
CN1802152A (zh) * 2002-08-01 2006-07-12 艾斯根公司 用谷氨酰胺改善癌症的治疗
US20040213837A1 (en) * 2002-08-05 2004-10-28 Sankaram Mantripragada Oil-core compositions for the sustained release of hydrophobic drugs
ITMI20022323A1 (it) * 2002-10-31 2004-05-01 Maria Rosa Gasco Composizioni farmaceutiche atte al trattamento di malattie oftalmiche.
WO2005023767A2 (en) 2003-09-10 2005-03-17 Brentwood Equities Ltd. Diastereomers of 4-aryloxy-3-hydroxypiperidines
ITMI20041151A1 (it) * 2004-06-09 2004-09-09 Maria Rosa Gasco Nanoparticelle lipidiche come agenti veicolanti per acidi nucleici procedimento per la loro preparazione e loro uso
AU2006339072A1 (en) * 2005-03-14 2007-10-25 Board Of Regents Of The University Of Texas System Bioactive FUS1 peptides and nanoparticle-polypeptide complexes
EP1874793A4 (en) * 2005-04-15 2008-12-24 Univ Texas DISTRIBUTION OF SIRNA BY NEUTRAL LIPID COMPOSITIONS
US20070110674A1 (en) * 2005-07-29 2007-05-17 Yuhong Xu Sono-active liposomes and lipid particles and use thereof as contrast agents and active-agent delivery systems
US20070154546A1 (en) * 2005-12-30 2007-07-05 Zhang Jack Y Sustained release pharmaceutical compositions
CA2661302A1 (en) * 2006-08-16 2008-02-21 Auspex Pharmaceuticals, Inc. Preparation and utility of opioid analgesics
WO2008109432A2 (en) * 2007-03-02 2008-09-12 The Board Of Regents Of The University Of Texas System Therapeutic targeting of interleukins using sirna in neutral liposomes
CN102112110A (zh) * 2008-06-06 2011-06-29 米尔纳医疗股份有限公司 用于RNAi试剂体内递送的新型组合物
KR101605932B1 (ko) 2009-12-18 2016-03-24 노파르티스 아게 Ｈｓｆ1-관련 질환을 치료하기 위한 유기 조성물
WO2011098449A1 (en) 2010-02-10 2011-08-18 Novartis Ag Methods and compounds for muscle growth
US20110250264A1 (en) 2010-04-09 2011-10-13 Pacira Pharmaceuticals, Inc. Method for formulating large diameter synthetic membrane vesicles
MX350595B (es) 2010-04-23 2017-09-11 Novartis Ag * Composiciones organicas para tratar enfermedades relacionadas con beta-enac.
US9770414B2 (en) * 2010-05-13 2017-09-26 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
JP6194248B2 (ja) 2010-10-28 2017-09-06 パシラ ファーマシューティカルズ インコーポレーテッド 非ステロイド性抗炎症薬の徐放性処方物
EP2630953B1 (en) 2010-12-27 2017-08-09 Terumo Kabushiki Kaisha Liposome composition and process for production thereof
WO2012109387A1 (en) 2011-02-08 2012-08-16 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
CA2864394C (en) 2011-03-02 2021-10-19 Jack Roth A method of predicting a response to a tusc2 therapy
EA201490553A1 (ru) 2011-09-02 2014-08-29 Новартис Аг Органические композиции для лечения связанных с hsf1 заболеваний
GB201119032D0 (en) * 2011-11-03 2011-12-14 Isis Innovation Multisomes: encapsulated droplet networks
CN104302768A (zh) 2012-01-09 2015-01-21 诺华股份有限公司 治疗β-联蛋白相关疾病的有机组合物
KR20150004414A (ko) 2012-05-02 2015-01-12 노파르티스 아게 Kras-관련 질환을 치료하기 위한 유기 조성물
WO2013168167A1 (en) 2012-05-10 2013-11-14 Painreform Ltd. Depot formulations of a hydrophobic active ingredient and methods for preparation thereof
CN110464709A (zh) 2012-08-10 2019-11-19 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
GB201219196D0 (en) 2012-10-25 2012-12-12 Isis Innovation Droplet assembly method
GB201219201D0 (en) 2012-10-25 2012-12-12 Isis Innovation Hydrogel network
WO2014087175A2 (en) 2012-12-07 2014-06-12 Isis Innovation Limited Droplet assembly by 3d printing
WO2014134255A2 (en) 2013-02-28 2014-09-04 Novartis Ag Organic compositions to treat epas1-related diseases
BR112015021586B1 (pt) 2013-03-14 2023-01-31 Fresenius Kabi Deutschland Gmbh Formulação de morfina farmacêutica injetável e kit
JP2016512455A (ja) 2013-03-14 2016-04-28 ベクトン ディッキンソン フランス エス．エー．エス． 酸素感受性薬物用の包装システム
US9693958B2 (en) 2013-03-15 2017-07-04 Cureport, Inc. Methods and devices for preparation of lipid nanoparticles
WO2015051135A2 (en) 2013-10-04 2015-04-09 Novartis Ag Organic compositions to treat hepcidin-related diseases
EP3169784B1 (en) 2014-07-16 2020-06-10 Arrowhead Pharmaceuticals, Inc. Rnai compositions to treat apoc3-related diseases
EP3186281B1 (en) 2014-08-28 2019-04-10 Halozyme, Inc. Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
WO2016038550A1 (en) 2014-09-11 2016-03-17 Novartis Ag Inhibition of prmt5 to treat mtap-deficiency-related diseases
EP3227446A1 (en) 2014-12-01 2017-10-11 Novartis AG Compositions and methods for diagnosis and treatment of prostate cancer
JP6316182B2 (ja) 2014-12-19 2018-04-25 富士フイルム株式会社 リポソームの製造方法及びリポソーム製造装置
WO2016193945A2 (en) 2015-06-05 2016-12-08 Novartis Ag Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
CN106546705B (zh) * 2015-09-21 2020-03-17 上海复旦张江生物医药股份有限公司 一种脂质体药物体外释放的测试方法
CN106546706B (zh) * 2015-09-21 2020-03-17 上海复旦张江生物医药股份有限公司 pH梯度主动载药法制备的脂质体药物的体外释放测试方法
EP3389650B1 (en) 2015-12-18 2022-01-12 The Board of Regents of The University of Texas System Therapeutics for preterm labor management
WO2018047148A1 (en) 2016-09-12 2018-03-15 Novartis Ag Compounds for the inhibition of mirna
BR112019007365A2 (pt) 2016-10-12 2019-07-09 Univ Texas métodos e composições para imunoterapia com tusc2
WO2018083606A1 (en) 2016-11-01 2018-05-11 Novartis Ag Methods and compositions for enhancing gene editing
EP3541815A4 (en) 2016-11-18 2020-07-15 Pacira Pharmaceuticals, Inc. ZINC MELXICAM COMPLEX MICROPARTICLE MULTIVESICULAR LIPOSOME FORMULATIONS AND METHODS OF MAKING THE SAME
KR102069670B1 (ko) * 2017-03-02 2020-01-23 단디바이오사이언스 주식회사 면역활성물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
US11530413B2 (en) 2017-07-21 2022-12-20 Novartis Ag Compositions and methods to treat cancer
CN111107853A (zh) 2017-09-11 2020-05-05 箭头药业股份有限公司 用于抑制载脂蛋白C-III (APOC3)的表达的RNAi试剂和组合物
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
US20210123016A1 (en) 2018-05-02 2021-04-29 Novartis Ag Regulators of human pluripotent stem cells and uses thereof
EP3870700A1 (en) 2018-10-24 2021-09-01 Codiak BioSciences, Inc. Methods to improve potency of electroporation
EP3920889A4 (en) 2019-02-08 2022-12-07 Board of Regents, The University of Texas System TELOMERASE-CONTAINING EXOSOMES FOR THE TREATMENT OF DISEASES RELATED TO AGE-RELATED ORGANDYS FUNCTION
WO2021216541A1 (en) 2020-04-20 2021-10-28 Board Of Regents, The University Of Texas System Biologically active dry powder compositions and method of their manufacture and use
WO2022040435A1 (en) 2020-08-19 2022-02-24 The Board Of Regents Of The University Of Texas System Nanodrugs for targeted drug delivery and use thereof
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
WO2023225160A1 (en) 2022-05-18 2023-11-23 The Children's Hospital Of Philadelphia Compositions and methods for inducible alternative splicing regulation of gene expression

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4078052A (en) 1976-06-30 1978-03-07 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Large unilamellar vesicles (LUV) and method of preparing same
CH624011A5 (no) 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
IT1111367B (it) 1978-11-17 1986-01-13 Serono Ist Farm Processo per la preparazione estemporanea di liposomi e liposomi cosi' ottenuti
US4310506A (en) 1979-02-22 1982-01-12 California Institute Of Technology Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species
US4394372A (en) 1980-12-22 1983-07-19 The Procter & Gamble Company Process for making lipid membrane structures
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
WO1995013796A1 (en) * 1993-11-16 1995-05-26 Depotech Corporation Vesicles with controlled release of actives
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
US5993850A (en) * 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
CA2181390C (en) * 1995-07-18 2001-04-24 Pankaj Modi Phospholipid formulations

Also Published As

Publication number Publication date
EP0971699A4 (en) 2006-05-24
NZ336843A (en) 2001-07-27
PT971699E (pt) 2015-02-04
IL131012A0 (en) 2001-01-28
EP2322143A1 (en) 2011-05-18
CA2851502C (en) 2016-03-15
JP2004262946A (ja) 2004-09-24
CA2851502A1 (en) 1998-08-06
US5962016A (en) 1999-10-05
JP3973646B2 (ja) 2007-09-12
DK0971699T3 (en) 2015-02-16
EP0971699A1 (en) 2000-01-19
JP3940177B2 (ja) 2007-07-04
CA2692302A1 (en) 1998-08-06
AU6317898A (en) 1998-08-25
CA2692302C (en) 2014-05-13
JP2001505224A (ja) 2001-04-17
NO993635L (no) 1999-09-27
NO993635D0 (no) 1999-07-27
EP2322143B1 (en) 2017-01-11
NO333827B1 (no) 2013-09-23
US5891467A (en) 1999-04-06
ES2529167T3 (es) 2015-02-17
WO1998033483A1 (en) 1998-08-06
CA2277956C (en) 2007-01-23
EP0971699B1 (en) 2014-11-26
NO329401B1 (no) 2010-10-11
CA2277956A1 (en) 1998-08-06
AU731038B2 (en) 2001-03-22

Similar Documents

Publication Publication Date Title
NO20100437L (no) Fremgangsmate for modifisering av frigjoringshastigheten av en biologisk aktiv forbindelse innkapslet i et multivesikulaert liposom, multivesikulaert liposom samt anvendelse derav
Wymann et al. The onset of the respiratory burst in human neutrophils. Real-time studies of H2O2 formation reveal a rapid agonist-induced transduction process.
Plack Jr et al. Cation/proton antiport systems in Escherichia coli. Absence of potassium/proton antiporter activity in a pH-sensitive mutant.
BR0215052A (pt) Composições acaricidas e métodos
NO950652L (no) Antitranspirasjonspreparat
HUP0301961A2 (hu) Enzimatikus festékek
NO964939D0 (no) Fremgangsmåte for fremstilling av virkestoffpreparater i form av en fast lösning av virkestoffet i en polymermatriks, samt virkestoffpreparater fremstilt ved hjelp av denne fremgangsmåte
WO2001085664A3 (en) Compounds and methods for regulating bacterial growth and pathogenesis
DK0971600T3 (da) Medicinsk levnedsmiddel til diabetikere
PT973413E (pt) Formulacoes nutricionais que contem lacto-n-neotetraose
ATE160285T1 (de) Haarfärbemittel
WO2002099853A3 (en) Temperature-controlled chuck and method for controlling the temperature of a substantially flat object
NO305552B1 (no) Fluorfenylsubstituerte alkenylkarboksylsyre-guanidiner, deres anvendelse til fremstilling av medikament eller diagnostikum sÕvel som medikament inneholdende dem
ES2139745T3 (es) Inhibidor de germinacion para patatas.
AU2696488A (en) Improved yields of 5.6-5.9 CST/100degrees C oil by wax isomerization employing low treat gas rates
NO306156B1 (no) Substituerte benzyloksykarbonylguanidiner, deres anvendelse til fremstilling av medikament eller diagnostikum sÕvel som legemidler inneholdende disse
AU1238100A (en) Topical vitamin composition
DE69630666D1 (de) Wirkstoff für verbesserten fettstoffwechsel
NO963780L (no) Direkte fluorescenskonjugert immunoassey for blodplateaktivering
DE59611282D1 (de) Zubereitungen zur Herstellung wirkstoffstabilisierter Kühlschmiermittelprodukte
Hicks et al. Oxidation of NADH by intact segments of soybean hypocotyls and stimulation by 2, 4-D
Gander et al. Bovine lens γ‐glutamylcysteine synthetase: inhibition by glutathione and adenine nucleotides
WO2001076546A3 (en) Method for colouring hair
BR0112947A (pt) Glicerólise em fase sólida
MXPA02010028A (es) Hipotensores.

Legal Events

Date Code Title Description
MK1K Patent expired